更短、更短的全时肺结核治疗具有成本效益并改善结果,支持印度肺结核计划推广使用。 Shorter, all-oral TB treatments are cost-effective and improve outcomes, supporting wider use in India’s TB program.

印度理事会的一项新研究发现,抗药性TB-BPaL和BPALM-Are为抗药性TBT-BPaLL和BPALM-Are提供的六个月全方位治疗具有成本效益,与较长的疗程相比,效果有所改善。 A new study by India’s ICMR finds that six-month, all-oral treatments for drug-resistant TB—BPaL and BPaLM—are cost-effective and improve outcomes compared to longer regimens. 每增加一个质量调整生命年(QALY),BPAL每增加一个质量调整生命年可节省379IRR,而BPALM每增加一个质量调整生命年只增加37IRR。 BPaL saves INR 379 per additional quality-adjusted life year (QALY), while BPaLM costs just INR 37 more per QALY gained. 这两种疗法都降低了保健费用,改善了遵守情况,并加快了恢复速度。 Both regimens reduce healthcare costs, improve adherence, and enable faster recovery. 调查结果支持根据印度的国家消除结核病方案扩大这些短期治疗,以加速消除结核病的努力。 The findings support expanding these shorter treatments under India’s National TB Elimination Programme to accelerate TB elimination efforts.